A group of eight molecules in the blood can be used as a biomarker to distinguish ALS from other neurodegenerative conditions ...

Clene will have an in-person meeting with the FDA before the end of November to discuss a potential CNM-Au8 accelerated ...

Columnist Juliet Taylor reflects on how the power of music helped her and her late husband, Jeff, navigate the difficulties ...

Amprion was awarded a $100,000 research grant to support studies on the causes of sporadic ALS that could improve diagnosis ...

A man with ALS became the first person to control an Amazon Alexa with his thoughts via an implanted brain-computer interface ...

Fourteen years into an ALS diagnosis, columnist Dagmar Munn decides in a visit to the dermatologist that she's earned her ...

Ractigen's therapy candidate RAG-17 was safe across all tested doses and showed early signs of effectiveness in SOD1-ALS ...

For columnist Kristin Neva, whose husband, Todd, has ALS, everyday moments like her son's football game are filled with both ...

The Phase 1 clinical trial is expected to enroll about 60 participants to test how safe and well tolerated multiple doses of ...

NRG Therapeutics will use a new grant to advance preclinical studies of its class of oral small molecules as a potential ...

Certain rare genetic variants tied to Parkinson’s and other diseases raise the risk of developing ALS by more than three times, per a study.

A short course of treatment with RNS60, as an add-on to riluzole, extended the survival of ALS patients by about six months, ...